Aromatase inhibitors (AIs), one type of hormonal therapy, are indicated in the treatment of estrogen receptor–positive breast cancer in postmenopausal women (National Comprehensive Cancer Network, 2012). Here, CYP19A1 is linked to breast carcinoma.